Typically, autoimmune sensorineural hearing loss has been described as a slowly progressive, asymmetric hearing loss that is responsive to medications traditionally used in the treatment of other autoimmune conditions. These medications include steroids and cytotoxic drugs. Inciting factors in autoimmune inner ear disease are rarely cited. We describe a case of episodic sudden hearing loss triggered consistently by environmental noise. The hearing loss was responsive to steroids at the time of each occurrence and was determined to be autoimmune. This case raises questions about the relationship between autoimmune inner ear disease and sensitivity to environmental noise that warrant further research.
BoulasselMRDeggoujNTomasiJPGersdorffM. Inner ear autoantibodies and their targets in patients with autoimmune inner ear diseases. Acta Otolaryngol (Stockh)2001; 121: 28–34.
3.
VeldmanJE. Immunology of hearing: Experiments of nature. Am J Otol1989; 10: 183–7.
4.
HughesGBBarnaBPKinneySECalabreseLHNalepaNJ. Clinical diagnosis of immune inner-ear disease. Laryngoscope1988; 98: 251–3.
5.
VeldmanJE. Cochlear and retrocochlear immune-mediated inner ear disorders. Pathogenetic mechanisms and diagnostic tools. Ann Otol Rhinol Laryngol1986; 95: 535–40.
6.
SismanisAWiseCMJohnsonGD. Methotrexate management of immune-mediated cochleovestibular disorders. Otolaryngol Head Neck Surg1997; 116: 146–52.
7.
HoistadDLSchachernPAPaparellaMM. Autoimmune sensorineural hearing loss: A human temporal bone study. Am J Otolaryngol1998; 19: 33–9.
8.
VeldmanJERoordJJO'ConnorAFSheaJJ. Autoimmunity and inner ear disorders; an immune-complex mediated sensorineural hearing loss. Laryngoscope1984; 94: 501–7.
9.
ArnoldW. Systemic autoimmune diseases associated with hearing loss. Ann N Y Acad Sci1997; 830: 187–202.
10.
HarrisJP. Autoimmunity of the inner ear. Am J Otol1989; 10: 193–5.
11.
RyanAFGloddekBHarrisJP. Lymphocyte trafficking to the inner ear. Ann N Y Acad Sci1997; 830: 236–42.
12.
LasakJMSataloffRTHawkshawMCareyTELyonsKMSpiegelJR. Autoimmune inner ear disease: Steroid and cytotoxic drug therapy. Ear Nose Throat J2001; 80: 808–11,815–6, 818.
13.
HiroseKWenerMHDuckertLG. Utility of laboratory testing in autoimmune inner ear disease. Laryngoscope1999; 109: 1749–54.
14.
CareyTENairTSGrayJP. The search for the inner ear antigen of autoimmune sensorineural hearing loss. In: VeldmanJEPassaliDLimDJ, eds. New frontiers in immunobiology. The Hague, the Netherlands: Kugler, 1999: 67–74.
15.
HarrisJPRyanAF. Fundamental immune mechanisms of the brain and inner ear. Otolaryngol Head Neck Surg1995; 112: 639–53.
16.
ClementsPJ. Alkylating agents. In: DixonJFurstDE, eds. Second line agents in the treatment of rheumatic diseases. New York, NY: Marcel Dekker, 1991: 335–61.
MattesonELTirzamanOFacerGW. Use of methotrexate for autoimmune hearing loss. Ann Otol Rhinol Laryngol2000; 109: 710–4.
19.
SalleyLHJrGrimmMSismanisASpencerRFWiseCM. Methotrexate in the management of immune mediated cochleovestibular disorders: Clinical experience with 53 patients. J Rheumatol2001; 28: 1037–40.
20.
SismanisAThompsonTWillisHE. Methotrexate therapy for autoimmune hearing loss: A preliminary report. Laryngoscope1994; 104: 932–4.
